BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB’s 9th Annual Nordic Healthcare Conference

– Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia – AXL biomarker correlation supports bemcentinib’s proposed MoA, potential for Companion Diagnostic – Significant milestones expected over next 12 months BERGEN,…

Source: https://www.prnewswire.com:443/news-releases/bergenbio-presents-key-results-from-phii-programme-with-selective-axl-inhibitor-bemcentinib-at-dnb-s-9th-annual-nordic-healthcare-conference-884107479.html